Novartis: completes acquisition of eye drop Xiidra
(CercleFinance.com) - Novartis said it has completed the acquisition of Xiidra, a prescription treatment that was approved to treat the signs and symptoms of dry eye disease.
Xiidra is currently approved in the US, Canada and Australia: it is also under regulatory review in other markets, Novartis said.
This prescription eye drop solution previously belonged to the British company Shire.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Xiidra is currently approved in the US, Canada and Australia: it is also under regulatory review in other markets, Novartis said.
This prescription eye drop solution previously belonged to the British company Shire.
Copyright (c) 2019 CercleFinance.com. All rights reserved.